Inspection Record

Perry Drug — FDA 483 Findings

US FDAInspected 2015-07-23Published 2024-01-17 5 findingsTraining and personnelAseptic processing and sterility assuranceStability and storage

View the regulator's official source The source document is always the basis for judgement.

Findings

1Training and personnel

Clothing of personnel engaged in the manufacturing, processing, packing, and holding of drug products is not appropriate for the duties they perform.

2Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include validation of the sterilization process.

3Stability and storage

There is no written testing program designed to assess the stability characteristics of drug products.

4Aseptic processing and sterility assurance

Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such equipme nt .

5Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for monitoring environmemal conditions.

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Perry Drug company profile — full history US FDA documents, 2024 Go to Findings search